- ROUNDTABLE: Pharmacy’s future in sync with technology
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- President Obama addresses health reform during State of the Union, industry responds
- Teva announces launch of Adasuve
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
NEW YORK — Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.
Bloomberg reported that the Supreme Court upheld a ruling that allowed Otsuka to block Canadian generic drug maker Apotex from marketing a version of the antipsychotic Abilify (aripiprazole), which Otsuka co-markets with Bristol-Myers Squibb.
Apotex attempted to argue that because any person with the right skills could create a version of Abilify's active ingredient sufficiently identical to the original, and that the ingredient belonged to a class of drugs that had existed since the early 1980s. But the high court upheld a ruling in a lower court rejecting those claims.